[go: up one dir, main page]

WO2010106269A3 - Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique - Google Patents

Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2010106269A3
WO2010106269A3 PCT/FR2010/050447 FR2010050447W WO2010106269A3 WO 2010106269 A3 WO2010106269 A3 WO 2010106269A3 FR 2010050447 W FR2010050447 W FR 2010050447W WO 2010106269 A3 WO2010106269 A3 WO 2010106269A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
groups
therapeutics
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2010/050447
Other languages
English (en)
Other versions
WO2010106269A2 (fr
Inventor
Geneviève ESTENNE-BOUHTOU
Abdel-Kader Mafroud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0901219A external-priority patent/FR2943056A1/fr
Priority claimed from FR0901810A external-priority patent/FR2944283B1/fr
Priority to AU2010224720A priority Critical patent/AU2010224720A1/en
Priority to EP10715932A priority patent/EP2408763A2/fr
Priority to SG2011066867A priority patent/SG174434A1/en
Priority to CA2755526A priority patent/CA2755526A1/fr
Priority to RU2011141778/04A priority patent/RU2011141778A/ru
Priority to CN2010800121453A priority patent/CN102356074A/zh
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to BRPI1009496A priority patent/BRPI1009496A2/pt
Priority to JP2012500292A priority patent/JP2012520345A/ja
Priority to MX2011009677A priority patent/MX2011009677A/es
Publication of WO2010106269A2 publication Critical patent/WO2010106269A2/fr
Publication of WO2010106269A3 publication Critical patent/WO2010106269A3/fr
Priority to IL215104A priority patent/IL215104A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Les composés de l'invention répondent à la formule générale (I) dans laquelle R représente un atome d'hydrogène ou un groupe choisi parmi les groupes (C1-C6)aIkVIe, (C3-C7)-cycloalkyle, benzyle ou allyle éventuellement substitué par un ou plusieurs groupes choisis indépendamment l'un de l'autre parmi les atomes d'halogène, les groupes (C3-C7)-cycloalkyle, (C1-C6)alkyle, (C1-C6)BlCOXy, hydroxy; R1 représente un groupe phényle ou naphtyle, éventuellement substitué par un ou plusieurs substituants choisis indépendamment l'un de l'autre parmi les atomes d'halogène, les groupes (CrC6)alkyle, (C1-C6)BlCOXy, halo-(C1-C6)alkyle, hydroxy, halo-(C1C6)alcoxy, (C1-C6)alkyle-thio, (C1-C6)alkyle-SO, (C1C6)alkyle-SO2; Het représente un groupe hétéroaryle; R2 représente un ou plusieurs substituants choisis parmi l'atome d'hydrogène, les atomes d'halogène, les groupes halo-(d- C6)alkyle, (C1C6)alkyle, (C3-C7)cycloalkyle, (C3-C7)-cycloalkyl-(C1-C3)alkyle, (C1- C6)alcoxy, benzyl, (C1C6)alkyle-thio, (C1C6)alkyle-SO, (C1C6)alkyle-SO2; à l'état de base ou de sel d'addition à un acide. Utilisation en thérapeutique et procédé de synthèse.
PCT/FR2010/050447 2009-03-16 2010-03-15 Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique Ceased WO2010106269A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2012500292A JP2012520345A (ja) 2009-03-16 2010-03-15 Ｎ−［（２−アザ−ビシクロ［２．１．１］ヘキス−１−イル）−アリール−）メチル］−ヘテロベンズアミドの誘導体、その調製および治療におけるその用途
MX2011009677A MX2011009677A (es) 2009-03-16 2010-03-15 Derivados de n-[(2-aza-biciclo[2.1.1]hex-1-il)-aril-metil]-heterob enzamida, su preparacion y su aplicacion en terapeutica.
BRPI1009496A BRPI1009496A2 (pt) 2009-03-16 2010-03-15 derivados de n-[(2-aza-biciclo[2.1.1] hex-1-il)-aril-metil]-heterobenzamida, o respectivo preparo e a respectiva aplicação em terapêutica
SG2011066867A SG174434A1 (en) 2009-03-16 2010-03-15 Derivatives of n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics
CA2755526A CA2755526A1 (fr) 2009-03-16 2010-03-15 Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique
RU2011141778/04A RU2011141778A (ru) 2009-03-16 2010-03-15 Производные n-[(2-азабицикло[2.1.1]гекс-1-ил)арилметил]гетеробензамида, их получение и их применение в терапии
CN2010800121453A CN102356074A (zh) 2009-03-16 2010-03-15 N-[(2-氮杂-二环[2.1.1]己-1-基)-芳基-)甲基]-杂苯甲酰胺的衍生物，它们的制备和它们在治疗中的应用
AU2010224720A AU2010224720A1 (en) 2009-03-16 2010-03-15 Derivatives of N-[(2-aza-bicyclo [2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics
EP10715932A EP2408763A2 (fr) 2009-03-16 2010-03-15 Derives de n-ý(2-aza-bicycloý2.1.1¨hex-1-yl)-aryl-methyl¨-heterobenzamide, leur preparation et leur application en therapeutique
IL215104A IL215104A0 (en) 2009-03-16 2011-09-12 Derivatives of n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, preparation thereof and application of same in therapeutics

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0901219A FR2943056A1 (fr) 2009-03-16 2009-03-16 Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
FR09/01219 2009-03-16
FR09/01810 2009-04-14
FR0901810A FR2944283B1 (fr) 2009-04-14 2009-04-14 Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
WO2010106269A2 WO2010106269A2 (fr) 2010-09-23
WO2010106269A3 true WO2010106269A3 (fr) 2010-12-02

Family

ID=42740053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/050447 Ceased WO2010106269A2 (fr) 2009-03-16 2010-03-15 Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique

Country Status (14)

Country Link
EP (1) EP2408763A2 (fr)
JP (1) JP2012520345A (fr)
KR (1) KR20110132565A (fr)
CN (1) CN102356074A (fr)
AR (1) AR075837A1 (fr)
AU (1) AU2010224720A1 (fr)
CA (1) CA2755526A1 (fr)
IL (1) IL215104A0 (fr)
MX (1) MX2011009677A (fr)
RU (1) RU2011141778A (fr)
SG (1) SG174434A1 (fr)
TW (1) TW201036980A (fr)
UY (1) UY32495A (fr)
WO (1) WO2010106269A2 (fr)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012128A1 (fr) * 1991-01-14 1992-07-23 The Du Pont Merck Pharmaceutical Company Analgesiques a base de composes heterocycliques d'azote(amidomethyle)
WO2004013100A2 (fr) * 2002-07-29 2004-02-12 Sanofi-Aventis Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2004013101A2 (fr) * 2002-07-29 2004-02-12 Sanofi-Aventis Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2005037785A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique
WO2005037782A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2005037783A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Composes tricycliques comme inhibiteurs de transport de glycine
WO2008018639A2 (fr) * 2006-08-11 2008-02-14 Taisho Pharmaceutical Co., Ltd. Inhibiteur de transporteurs de glycine
WO2009013535A1 (fr) * 2007-07-23 2009-01-29 Astrazeneca Ab Dérivés de 2-azabicyclo(2,2,2)octane en tant que modulateurs du récepteur transporteur de type i de la glycine

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012128A1 (fr) * 1991-01-14 1992-07-23 The Du Pont Merck Pharmaceutical Company Analgesiques a base de composes heterocycliques d'azote(amidomethyle)
WO2004013100A2 (fr) * 2002-07-29 2004-02-12 Sanofi-Aventis Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2004013101A2 (fr) * 2002-07-29 2004-02-12 Sanofi-Aventis Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2005037785A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique
WO2005037782A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2005037792A1 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique
WO2005037783A2 (fr) * 2003-10-17 2005-04-28 Sanofi-Aventis Composes tricycliques comme inhibiteurs de transport de glycine
WO2008018639A2 (fr) * 2006-08-11 2008-02-14 Taisho Pharmaceutical Co., Ltd. Inhibiteur de transporteurs de glycine
WO2009013535A1 (fr) * 2007-07-23 2009-01-29 Astrazeneca Ab Dérivés de 2-azabicyclo(2,2,2)octane en tant que modulateurs du récepteur transporteur de type i de la glycine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LOWE III J A: "Novel inhibitors of the type 1 transporter of glycine (GlyT1) as antip", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 15, no. 11, 1 November 2005 (2005-11-01), pages 1657 - 1662, XP002372471, ISSN: 1354-3776 *

Also Published As

Publication number Publication date
IL215104A0 (en) 2011-12-29
MX2011009677A (es) 2011-09-30
WO2010106269A2 (fr) 2010-09-23
AU2010224720A1 (en) 2011-10-06
SG174434A1 (en) 2011-10-28
CA2755526A1 (fr) 2010-09-23
TW201036980A (en) 2010-10-16
EP2408763A2 (fr) 2012-01-25
AR075837A1 (es) 2011-04-27
JP2012520345A (ja) 2012-09-06
KR20110132565A (ko) 2011-12-08
UY32495A (es) 2010-10-29
CN102356074A (zh) 2012-02-15
RU2011141778A (ru) 2013-04-27

Similar Documents

Publication Publication Date Title
WO2008108378A3 (fr) Dérivé bicyclique d&#39;oxomorpholine
BRPI0507005A (pt) compostos, composições farmacêuticas, uso de um composto, e, método de preparo de uma composição farmacêutica
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
WO2009016460A3 (fr) Composés pyrazoles
MXPA06013534A (es) Compuesto de cinamida.
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
WO2010089510A3 (fr) Dérivés d&#39;azaspiranyl-alkylcarbamates d&#39;hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
WO2009118473A3 (fr) Composés dérivés d&#39;azétidines, leur préparation et leur application en thérapeutique
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés
ZA201002139B (en) New compounds as adenosine a1 receptor antagonists
WO2009047499A3 (fr) Procédés de préparation de palipéridone et de ses sels pharmaceutiquement acceptables et d&#39;intermédiaires pour une utilisation dans les procédés
WO2009007536A3 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
BRPI1009497A2 (pt) Derivados de n-[(6-aza-biciclo[3.2.1] oct-5-il)-aril- metil]-heterobenzamida, o respectivo preparo e a respectiva aplicação em terapêutica
WO2013190123A8 (fr) Dérivés de pyrimidinone en tant qu&#39;agents anti-malaria
WO2010106269A3 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique
PH12013501897A1 (en) Azole derivative
WO2009106748A3 (fr) Dérivés de n-phenyl-imidazo[1,2-a]pyridine-2-carboxamides, leur préparation et leur application en thérapeutique
WO2010067010A3 (fr) Derives de morphine-6-glucuronide, leur preparation et leur application en therapeutique
WO2008090200A3 (fr) Dérivés de 2- piperazin-1-yl-3h-imidazo[4,5-b]pyridine
SG153774A1 (en) New 1h-indol-1-yl-urea compounds, a process for their preparation and pharmaceutical compositions containing them
MX2011010929A (es) Derivados de n-[7-aza-biciclo[2.2.1]hept-1-il)-aril-metil]-benzami da, su preparacion y su uso en terapeutica.
WO2010013474A1 (fr) Promoteur de la production de céramide
TH73885A (th) อนุพันธ์ 4,5-ไดไฮโดร-1h-ไพราโซลที่ถูกแทนที่สามที่ที่ 1,3,5 ที่มีการออกฤทธิ์ cb1-แอนตาโกนิสติก
HK1170485A1 (zh) 1，2，4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
TW200738637A (en) Compounds having activity at NK3 receptor and uses thereof in medicine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080012145.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715932

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 1767/MUMNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010715932

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2755526

Country of ref document: CA

Ref document number: 2010224720

Country of ref document: AU

Ref document number: MX/A/2011/009677

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20117021438

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012500292

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2010224720

Country of ref document: AU

Date of ref document: 20100315

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011141778

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1009496

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1009496

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110915